Triple
T19157737
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | ansuvimab |
E468967
|
entity |
| Predicate | distinguishedFrom |
P1612
|
FINISHED |
| Object | REGN-EB3 |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: REGN-EB3 | Statement: [ansuvimab, distinguishedFrom, REGN-EB3]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: REGN-EB3 Context triple: [ansuvimab, distinguishedFrom, REGN-EB3]
-
A.
REGN-EB3
chosen
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
B.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
C.
REGN
REGN is the stock ticker symbol for Regeneron Pharmaceuticals, a major U.S.-based biotechnology company known for developing innovative antibody-based therapies.
-
D.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
E.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd084ff48190ac0f8c46ee722629 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5eeba91a081909c04d61d6117da06 |
completed | April 20, 2026, 9:15 a.m. |
Created at: April 10, 2026, 12:06 p.m.